Episodebeskrivelse
Pass-through status is not a one-time CMS classification. It is a constantly moving pipeline, with new drugs entering protected payment status while others transition into standard OPPS reimbursement.
In this episode of Revenue RX, we use the July 1, 2026 OPPS updates as a real-world case study to break down what changed and what pharmacy revenue cycle teams should be watching.
We cover newly coded drugs, biologics, and radiopharmaceuticals entering status indicator G, biosimilars receiving their own pass-through status, products exiting pass-through and moving to status indicator K, and…

